ICAgen, Sphinx will collaborate in drug screening program
Executive Summary
NC biopharm companies ICAgen (Ion Channel Advances, biological and computer-simulated assays to discover ion channel drugs) and Sphinx Pharmaceuticals formed a research alliance to identify and develop compounds to modulate cellular ion channels.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice